Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bristol Myers Squibb
Biotech
ESMO: Bristol Myers axes Immatics' bispecific after $150M bet
Immatics is the latest partner to get a termination notice, leaving it in full control of a bispecific that BMS picked up for $150 million in 2021.
Nick Paul Taylor
Sep 16, 2024 6:59am
ESMO: Regeneron's Opdualag rival shows 57% response rate
Sep 14, 2024 3:00am
ESMO: Cancer vaccine and Keytruda deliver in phase 2 trial
Sep 14, 2024 2:30am
Candid flashes big ambitions with $370M debut
Sep 9, 2024 9:00am
ArsenalBio raises $325M, pivots away from former lead asset
Sep 4, 2024 8:00am
New data show how Bayer's asundexian failed to prevent strokes
Sep 1, 2024 3:40am
